Virtu Financial’s Calidi Biotherapeutics CLDI Stock Holding History

Virtu Financial’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,736	Closed	-$18K	–	1678
2026 Q1	$18K	Buy	4,736 +3,408	+257%	+$41K	﹤0.01%	1404
2025 Q4	$25K	Buy	+1,328	New	+$31.3K	﹤0.01%	1386
2025 Q3	–	Sell	-53	Closed	-$2K	–	1541
2025 Q2	$2K	Sell	53 -232	-81%	-$18K	﹤0.01%	1362
2025 Q1	$31K	Sell	285 -98	-26%	-$17.9K	﹤0.01%	1067
2024 Q4	$84K	Buy	+383	New	+$115K	﹤0.01%	1059
2024 Q3	–	Sell	-14	Closed	-$5K	–	1442
2024 Q2	$5K	Sell	14 -8	-36%	-$4.09K	﹤0.01%	1180
2024 Q1	$24K	Buy	+22	New	+$36K	﹤0.01%	1138
2023 Q2	–	Sell	-16	Closed	-$312K	–	1580
2023 Q1	$312K	Buy	16 +9	+129%	+$177K	0.03%	529
2022 Q4	$131K	Sell	7 -34	-83%	-$651K	0.02%	862
2022 Q3	$784K	Buy	+41	New	+$786K	0.07%	253

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial's CLDI Position: Q2 2026 in Review

Virtu Financial sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 4,736 shares — an estimated $18K sold.

Virtu Financial first reported a position in CLDI in Q3 2022 and held it in 10 quarters. The position peaked at $784K in Q3 2022. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

Virtu Financial reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 4,736 Calidi Biotherapeutics shares in Q2 2026, an estimated $18K.
Virtu Financial first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 10 quarters.
Virtu Financial's Calidi Biotherapeutics position peaked at $784K in Q3 2022.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.